Ketotifen Unit Dose Stulln (Ketotifen)

Ketotifen blocks H1 histamine receptors and stabilises mast cells, preventing the release of histamine and other inflammatory mediators. This dual action reduces vascular leakage, edema, and nerve activation, leading to decreased itching, redness, and swelling in the conjunctiva.

The dosing regimen for Ketotifen Unit Dose Stulln is determined by the prescribing clinician based on the severity of symptoms and patient factors. Typical practice involves instilling one unit‑dose drop into the affected eye(s) as directed by the healthcare professional.

Safety data for ketotifen eye drops in pregnancy and lactation are limited. The product should only be used if the potential benefit outweighs any possible risk, and the decision should be made by a qualified healthcare provider after evaluating the individual situation.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ketotifen combines H1‑receptor antagonism with mast‑cell stabilisation, offering both immediate symptom relief and longer‑term reduction of allergic inflammation. Other ocular antihistamines may provide only receptor blockade, so ketotifen can be advantageous for patients needing both rapid and sustained control of allergic eye disease.

Ketotifen Unit Dose Stulln should be stored at room temperature, below 25 °C, in its original packaging. Protect the unit‑dose vials from direct sunlight, moisture and extreme temperature fluctuations to maintain product stability and sterility.

The product is supplied as single‑use unit‑dose vials. The patient should wash hands, remove the protective cap, and instill the drop directly onto the conjunctival sac of the affected eye(s) without touching the tip to any surface. Contact lenses should be removed before application.

Serious risks, although rare, include severe allergic reactions such as eyelid or facial swelling, acute eye pain, sudden loss of vision, and corneal ulceration. Any of these symptoms require immediate medical attention and discontinuation of the product.

Patients with a known hypersensitivity to ketotifen or any component of the formulation should avoid using the product. Caution is also advised for individuals with narrow‑angle glaucoma, active ocular infections, or those wearing contact lenses during treatment unless instructed otherwise by an eye‑care professional.